E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
inflammation of the kidneys caused by autoimmune disease |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Immune system processes [G12] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10025140 |
E.1.2 | Term | Lupus nephritis |
E.1.2 | System Organ Class | 10038359 - Renal and urinary disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescents with active LN. |
|
E.2.2 | Secondary objectives of the trial |
•To assess the safety and tolerability of voclosporin over 24 weeks in adolescents with active LN.
•To assess the pharmacokinetics (PK) and pharmacodynamics (PD) of voclosporin in adolescents with LN.
•To assess the palatability and acceptability of voclosporin softgel capsules.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male or female subjects 12 to <18 years of age at the time of screening
2. Previous diagnosis of SLE according to the 2019 EULAR/ACR classification criteria.
3. Subjects with kidney biopsy result, with evidence of active nephritis
Refer to protocol for full list of inclusion criteria |
|
E.4 | Principal exclusion criteria |
1. Estimated glomerular filtration rate of <60 mL/min/1.73 m2 at screening confirmed before randomization
2. Use of immunosuppression biologic agents within 12 weeks prior to randomization
3. Use of cyclophosphamide, cholestyramine, calcineurin inhibitors, live attenuated vaccines and initiation or dose changes in ARBs and ACEi within 4 weeks prior to randomisation
4. Use of Strong CYP3A4/5 inhibitors and inducers within 2 weeks prior to randomization
5. Currently requiring renal dialysis or expected to require dialysis during the study period
6. A previous kidney transplant or planned transplant within study treatment period.
7. Any medical condition which, in the Investigator’s judgment, may be associated with increased risk to the subject or may interfere with study assessments or outcomes.
8. Subjects who are pregnant, breast feeding or, if of childbearing potential, not using adequate contraceptive precautions
Refer to protocol for full list of exclusion criteria |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Renal response at Week 24 will be adjudicated by the Clinical Endpoints Committee (CEC) based on the following parameters:
• UPCR of ≤0.5 mg/mg, and
• eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of >20%, and
• Received no rescue medication for LN, and
• Did not receive >10 mg/day prednisone for ≥3 consecutive days or for ≥7 days in total between Week 16 and Week 24. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Time to UPCR of ≤0.5 mg/mg.
• UPCR of ≤0.7 mg/mg at Week 24.
• Time to UPCR of ≤0.7 mg/mg.
• Partial renal response as defined by ≥50% reduction from baseline in UPCR at Week 24.
• Time to 50% reduction in UPCR from baseline.
• Proportion of subjects with renal flare, defined as: o At least a doubling in UPCR to ≥1.0 mg/mg for Class III, IV-S, or Class IVG alone or in combination with Class V or ≥2.0 mg/mg for Class V only OR o At least a doubling in serum creatinine to ≥120 μmol/L (~1.37 mg/dL).
• Proportion of subjects with extra-renal flare, defined as an increase in 4-6 points on the extra-renal domains in the Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at Week 24.
• Change from baseline in UPCR at each time point up to and including Week 24.
• Change from baseline in eGFR, urine protein and serum creatinine at each time point up to and including Week 24.
• Proportion of subjects with a decrease in eGFR >30% at each time point up to and including Week 24.
• Change from screening in immunology parameters (complement 3 (C3), C4, and anti-double-stranded DNA) at each time point up to and including Week 24.
• Change from baseline in the SELENA-SLEDAI score at Week 24.
• Proportion of subjects with prednisone equivalent <7.5 mg/day at Week 24.
• Adverse events (AE) profile, electrocardiograms (ECGs) and routine biochemical and hematological assessment over time up to and including Week 24 plus Safety Follow-Up period.
• PK parameters and calcineurin inhibition of voclosporin at steady state (Week 8)
• Palatability and acceptability of voclosporin softgel capsules |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Refer to schedule of events |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability and palatability and acceptability of voclosporin softgel capsules |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 4 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Colombia |
France |
Israel |
Italy |
Korea, Republic of |
Mexico |
Netherlands |
Peru |
Spain |
Taiwan |
Thailand |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 0 |